Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shield TherapeuticsFRA:1JS +1.20% Cash-to-Debt is 0.39 as of Dec. 2025, which is 99% below its 10-year median of 72.00. The stock has 5 warning signs investors should review. Among 982 Drug Manufacturers companies, Shield Therapeutics ranks worse than 66.29% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Shield Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2025 was 0.39.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Shield Therapeuticscouldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Shield Therapeutics's Cash-to-Debt or its related term are showing as below:
FRA:1JS'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.25 Med: 72 Max: No Debt
Current: 0.39
During the past 12 years, Shield Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.25. And the median was 72.00.
FRA:1JS's Cash-to-Debt is ranked worse than 66.29% of 982
companies
in the Drug Manufacturers industry
Industry Median: 0.98
vs FRA:1JS: 0.39
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Shield Therapeutics Cash-to-Debt Related Terms
Shield Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Shield Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
FRA:1JS vs ZTS, UTHR, VTRS: Cash-to-Debt Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shield Therapeutics Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Shield Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shield Therapeutics (FRA:1JS) has a Cash-to-Debt of 0.39 as of Dec. 2025. This is 99% below median its historical median of 72.00. Over the past decade, Shield Therapeutics' Cash-to-Debt has ranged from 0.25 to 10,000.00. According to the industry distribution chart, Shield Therapeutics ranks #651 out of 982 companies in the Drug Manufacturers industry, placing it in the top 66.3%.
Is Shield Therapeutics' Cash-to-Debt too high?
Shield Therapeutics' current Cash-to-Debt of 0.39 is 99% below median its 10-year median of 72.00. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 10,000.00. The Drug Manufacturers industry median Cash-to-Debt is 0.98. Shield Therapeutics' value of 0.39 is 60.2% below this industry median. Based on the distribution chart, Shield Therapeutics ranks #651 out of 982 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Shield Therapeutics' Cash-to-Debt compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shield Therapeutics ranks #651 out of 982 companies for Cash-to-Debt. This places Shield Therapeutics in the lower half of its industry. The industry median Cash-to-Debt is 0.98. Shield Therapeutics' value of 0.39 is 60.2% below this benchmark. Historically, Shield Therapeutics' own Cash-to-Debt has ranged from 0.25 to 10,000.00 over the past decade. While the company's 10-year median is 72.00 vs. the industry median of 0.98, Shield Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.98, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shield Therapeutics's current Cash-to-Debt of 0.39 is 60.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shield Therapeutics's current Cash-to-Debt is 0.39, which is 99% below median its own 10-year median of 72.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (FRA:1JS) is currently considered Possible Value Trap. The stock's GF Value™ is €0.10, compared to a current price of €0.04 — trading 58% below its estimated fair value. The current Cash-to-Debt is 0.39, which is 99% below median its 10-year median of 72.00 and 60.2% below the Drug Manufacturers industry median of 0.98. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Shield Therapeutics (FRA:1JS), the current Cash-to-Debt is 0.39 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1JS has been successfully added to your 
